An evaluation of the effects on the ovaries of hyperbaric oxygen therapy in a rat model of premature ovarian failure created with cyclophosphamide

Fulya Çağlı; Mehmet Akif Baktır; Mehmet Dolanbay; Esra Balcıoğlu; Ahmet Cumaoğlu; Mustafa Ermiş; Enes Karaman; Betül Yalçın; Ercan Mustafa Aygen

doi:10.4274/tjod.galenos.2023.47817

An evaluation of the effects on the ovaries of hyperbaric oxygen therapy in a rat model of premature ovarian failure created with cyclophosphamide

Turk J Obstet Gynecol. 2023 Mar 10;20(1):46-52. doi: 10.4274/tjod.galenos.2023.47817.

Authors

Fulya Çağlı¹, Mehmet Akif Baktır², Mehmet Dolanbay¹, Esra Balcıoğlu³, Ahmet Cumaoğlu⁴, Mustafa Ermiş⁵, Enes Karaman¹, Betül Yalçın³, Ercan Mustafa Aygen¹

Affiliations

¹ Erciyes University Faculty of Medicine, Department of Obstetrics and Gynecology, Kayseri, Turkey.
² Erciyes University Faculty of Medicine, Department of Physiology, Kayseri, Turkey.
³ Erciyes University Faculty of Medicine, Department of Histology and Embryology, Kayseri, Turkey.
⁴ Erciyes University Faculity of Pharmacy, Department of Biochemistry, Kayseri, Turkey.
⁵ Erciyes University, Good Clinical Practice and Research Center, Kayseri, Turkey.

Abstract

Objective: To evaluate hyperbaric oxygen therapy (HBO) based on ovarian histology, total antioxidant status (TAS), total oxidant status (TOS), and anti-müllerian hormone (AMH), in the ovarian insufiency (POI) model created with cyclophosphamide (CYP).

Materials and methods: The rats were separated into 3 groups of the control group (n=6), the CYP group (n=6), and the CYP+HBO group (n=6). The rats in the CYP group and the CYP+HBO group were injected intraperitoneally with 200 mg/kg CYP on day 1, followed by 8 mg/kg/day for 14 days to create POI. From the 15^th day onwards, the rats in the CYP+HBO group were placed in a hyperbaric cabin and exposed to 100% oxygen at 2.4 atm pressure for one h, and were then returned to their cages at the end of the hour.

Results: A statistically significant decrease was determined in the primordial and primary follicle counts in the CYP group compared with the control group (p<0.05). In the CYP+HBO group, a statistically significant increase was determined in the primordial and primary follicle counts (p<0.05). The serum AMH levels were seen to be significantly decreased in the CYP group compared with both the control group and the CYP+HBO groups. The HBO was seen to decrease TOS and increase TAS.

Conclusion: HBO could be an alternative treatment to minimize the effect of ovarian follicle loss caused by CYP, which is used for treating tumors that commonly occur in young females of reproductive age.

Keywords: Anti-müllerian hormone; cyclophosphamide; hyperbaric oxygen; ovarian failure.